Skip to main content

Bizily Scott's Form 4 filing

4D Molecular Therapeutics, Inc. (FDMT) · filed Sep 22, 2026

Accession no.
0001193125-26-398204
Filed
Sep 22, 2026, 6:43 PM ET
Trade date
Sep 16, 2026
Filing delay
6 daysLate
Rule 10b5-1 plan
Checked

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $22.3K. It was filed 6 days after the trade, past the 2-business-day deadline.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Bizily ScottCIK 0001920738Officer (Chief Legal Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 16, 2026Common StockMOption exerciseAcquired+1,635$4.14+$6,768.910,252Direct
Sep 16, 2026Common StockSSaleDisposed−1,635$13.65−$22,317.758,617Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Sep 16, 2026Common StockMOption exerciseDisposed−1,635$0.00$058,066Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Read the full filing on SEC EDGAR (opens in a new tab)